Δ9-Tetrahydrocannabinol-like discriminative stimulus effects of compounds commonly found in K2/Spice

Behavioural Pharmacology

Volumn 25, Issue 8, 2014, Pages 750-757

  Gatch, Michael B ^a   Forster, Michael J ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Abuse liability; Cannabinoids; Drug discrimination; Locomotor activity; Mouse; Rat

Indexed keywords

1 (5 FLUOROPENTYL) 3 (1 NAPHTHOYL)INDOLE; 1 BUTYL 3 (1 NAPHTHOYL)INDOLE; 3 (1 NAPHTHOYL) 1 PENTYLINDOLE; CANNABINOID RECEPTOR AGONIST; CP 47,497 C8 HOMOLOG; DRONABINOL; JWH 200; JWH 203; JWH 250; UNCLASSIFIED DRUG; CP 47497; CYCLOHEXANOL DERIVATIVE; INDOLE DERIVATIVE; JWH-073; NAPHTHALENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANNABIS USE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG ABUSE; INJECTION; LOCOMOTION; MALE; MOUSE; NONHUMAN; ANIMAL; CHEMISTRY; DRUG EFFECTS; INSTRUMENTAL CONDITIONING; MOTOR ACTIVITY; PERCEPTIVE DISCRIMINATION; RAT; SPICE; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; CANNABINOID RECEPTOR AGONISTS; CONDITIONING, OPERANT; CYCLOHEXANOLS; DISCRIMINATION (PSYCHOLOGY); DRONABINOL; INDOLES; MALE; MOTOR ACTIVITY; NAPHTHALENES; RATS; RATS, SPRAGUE-DAWLEY; SPICES; TIME FACTORS;

EID: 84927940122     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000093     Document Type: Article

References (33)

1. Atwood BK, Huffman J, Straiker A, Mackie K (2010). JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 160:585-593.
2. Atwood BK, Lee D, Straiker A, Widlanski TS, Mackie K (2011). CP47,497-C8 and JWH073, commonly found in 'Spice' herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur J Pharmacol 659:139-145.
3. Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreirós N (2009). 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832-837.
4. Balster RL (1991). Drug abuse potential evaluation in animals. Br J Addict 86:1549-1558.
5. Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, et al. (2012). Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol 83:952-961.
6. Brents LK, Zimmerman SM, Saffell AR, Prather PL, Fantegrossi WE (2013). Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy. J Pharmacol Exp Ther 346:350-361.
7. Carroll FI, Blough BE, Abraham P, Mills AC, Holleman JA, Wolckenhauer SA, et al. (2009). Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem 52:6768-6781.
8. Craft RM, Wakley AA, Tsutsui KT, Laggart JD (2012). Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat. J Pharmacol Exp Ther 340:787-800.
9. Denooz R, Vanheugen JC, Frederich M, de Tullio P, Charlier C (2013). Identification and structural elucidation of four cannabimimetic compounds (RCS-4, AM-2201, JWH-203 and JWH-210) in seized products. J Anal Toxicol 37:56-63.
10. Fattore L, Fratta W (2011). Beyond THC: The New Generation of Cannabinoid Designer Drugs. Front Behav Neurosci 5:60.
11. Gatch MB, Forster MJ, Janowsky A, Eshleman AJ (2011). Abuse liability profile of three substituted tryptamines. J Pharmacol Exp Ther 338:280-289.
12. Gatch MB, Taylor CM, Forster MJ (2013). Locomotor stimulant and discriminative stimulus effects of 'bath salt' cathinones. Behav Pharmacol 24:437-447.
13. Ginsburg BC, Schulze DR, Hruba L, McMahon LR (2012). JWH-018 and JWH-073: δ9-tetrahydrocannabinol-like discriminative stimulus effects in monkeys. J Pharmacol Exp Ther 340:37-45.
14. Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL (2012). "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 21:320-326.
15. Heltsley R, Shelby MK, Crouch DJ, Black DL, Robert TA, Marshall L, et al. (2012). Prevalence of synthetic cannabinoids in U.S. athletes: initial findings. J Anal Toxicol 36:588-593.
16. Horton DB, Potter DM, Mead AN (2013). A translational pharmacology approach to understanding the predictive value of abuse potential assessments. Behav Pharmacol 24:410-436.
17. Hruba L, Ginsburg B, McMahon LR (2012). Apparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by δ9-tetrahydrocannabinol treatment in rhesus monkeys. J Pharmacol Exp Ther 342:843-849.
18. Hyatt WS, Fantegrossi WE (2014). δ9-THC exposure attenuates aversive effects and reveals appetitive effects of K2/'Spice' constituent JWH-018 in mice. Behav Pharmacol 25:253-257.
19. Järbe TU, Deng H, Vadivel SK, Makriyannis A (2011). Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (δ (9)-tetrahydrocannabinol) discrimination for rats. Behav Pharmacol 22:498-507.
20. Katsidoni V, Kastellakis A, Panagis G (2013). Biphasic effects of δ9-tetrahydrocannabinol on brain stimulation reward and motor activity. Int J Neuropsychopharmacol 16:2273-2284.
21. Lindigkeit R, Boehme A, Eiserloh I, Luebbecke M, Wiggermann M, Ernst L, Beuerle T (2009). Spice: a never ending story? Forensic Sci Int 191:58-63.
22. Logan BK, Reinhold LE, Xu A, Diamond FX (2012). Identification of synthetic cannabinoids in herbal incense blends in the United States. J Forensic Sci 57:1168-1180.
23. Marshell R, Kearney-Ramos T, Brents LK, Hyatt WS, Tai S, Prather PL, Fantegrossi WE (2014). In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid δ9-THC in mice: Inhalation versus intraperitoneal injection. Pharmacol Biochem Behav 124:40-47.
24. Musshoff F, Madea B, Kernbach-Wighton G, Bicker W, Kneisel S, Hutter M, Auwärter V (2014). Driving under the influence of synthetic cannabinoids ("Spice"): a case series. Int J Legal Med 128:59-64.
25. National Research Council (2011). Guide for the care and use of laboratory animals. 8th ed. Washington, DC: The National Academies Press.
26. Office of Forensic Sciences (2010). Scheduling update. Microgram Bulletin 44:1-16.
27. Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL (2013). Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol 269:100-108.
28. Rodriguez JS, McMahon LR (2014). JWH-018 in rhesus monkeys: differential antagonism of discriminative stimulus, rate-decreasing, and hypothermic effects. Eur J Pharmacol 740:151-159.
29. Showalter VM, Compton DR, Martin BR, Abood ME (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278:989-999.
30. Tofighi B, Lee JD (2012). Internet highs - seizures after consumption of synthetic cannabinoids purchased online. J Addict Med 6:240-241.
31. Wiley JL, Compton DR, Dai D, Lainton JA, Phillips M, Huffman JW, Martin BR (1998). Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther 285:995-1004.
32. Wiley JL, Lefever TW, Cortes RA, Marusich JA (2014). Cross-substitution of δ9-tetrahydrocannabinol and JWH-018 in drug discrimination in rats. Pharmacol Biochem Behav 124C:123-128.
33. Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K (2009). Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch Arztebl Int 106:464-467.